XML 61 R49.htm IDEA: XBRL DOCUMENT
v3.22.4

Collaboration, License, and Other Agreements - Schedule of Collaboration Revenue Earned From Sanofi (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Disaggregation of Revenue [Line Items] |  |  |
Revenues | $ 12,172.9 | $ 16,071.7 | $ 8,497.1
Sanofi Collaboration Agreement, Antibody | Other collaboration revenue | Regeneron's share of profits in connection with commercialization of antibodies |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 2,082.0 | 1,363.0 | 785.2
Sanofi Collaboration Agreement, Antibody | Other collaboration revenue | Sales-based milestones earned |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 100.0 | 50.0 | 50.0
Sanofi Collaboration Agreement, Antibody | Other collaboration revenue | Reimbursement for manufacturing of commercial supplies |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 633.7 | 488.8 | 368.0
Sanofi Collaboration Agreement, Antibody | Other collaboration revenue | Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 28.7 | 0.0 | 0.0
Sanofi Collaboration Agreement, Antibody | Reduction of R&D expense | Reimbursements of R&D expenses, net of Regeneron's obligation for its share of Sanofi R&D expenses |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 43.0 | 129.2 | 149.1
Sanofi Collaboration Agreement, Antibody | SG&A expense | Reimbursement of commercialization-related expenses |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 437.4 | 320.5 | 359.4
Sanofi Collaboration Agreement, Immuno-oncology | Other collaboration revenue | Regeneron's share of profits in connection with commercialization of antibodies |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 6.7 | (13.6) | (25.7)
Sanofi Collaboration Agreement, Immuno-oncology | Other collaboration revenue | Reimbursement for manufacturing of commercial supplies |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 4.6 | 14.0 | 8.9
Sanofi Collaboration Agreement, Immuno-oncology | Reduction of R&D expense | Reimbursement of R&D expenses |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 42.7 | 85.1 | 166.2
Sanofi Collaboration Agreement, Immuno-oncology | SG&A expense | Reimbursement of commercialization-related expenses |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 41.4 | 89.6 | 64.7
Sanofi Collaboration Agreement, Immuno-oncology | SG&A expense | Regeneron's obligation for its share of Sanofi commercial expenses |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | (19.9) | (36.3) | (22.4)
Sanofi Collaboration Agreement, Immuno-oncology | Cost of goods sold | Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | (70.1) | (133.0) | (119.1)
Sanofi Collaboration Agreement, Immuno-oncology | Other operating income | Amounts recognized in connection with up-front payments received |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | $ 35.1 | $ 6.1 | $ 210.6

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_ShareOfProfitsLossesInConnectionWithCommercializationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_SalesBasedMilestoneEarnedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_OtherCollaborationAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_ReimbursementOfCommercializationRelatedExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_RegeneronsShareOfCommercialExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=regn_CostOfGoodsSoldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_SanofisShareOfLibtayoUSGrossProfitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |